Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2005 Nov;146(6):846-53.
doi: 10.1038/sj.bjp.0706384.

Reversal of cardiac dysfunction by selective ET-A receptor antagonism

Affiliations
Comparative Study

Reversal of cardiac dysfunction by selective ET-A receptor antagonism

Anthony Allan et al. Br J Pharmacol. 2005 Nov.

Abstract

The effectiveness of a selective endothelin receptor-A (ET-A) antagonist, A-127722 (approximately 10 mg kg(-1) day(-1) as 200 mg kg(-1) powdered food), to reverse existing cardiac remodelling and prevent further remodelling was tested in deoxycorticosterone acetate (DOCA)-salt hypertensive rats. Uninephrectomised rats (UNX) administered DOCA (25 mg every fourth day s.c.) and 1% NaCl in drinking water for 28 days developed hypertension (systolic blood pressure (BP): UNX 128+/-6 mmHg, DOCA-salt 182+/-5* mmHg; *P<0.05 vs UNX), left ventricular hypertrophy (UNX 1.99+/-0.06 mg kg(-1) body wt, DOCA-salt 3.30+/-0.08* mg kg(-1) body wt), decreased left ventricular internal diameter (UNX 6.69+/-0.18 mm, DOCA-salt 5.51+/-0.37* mm), an increased left ventricular monocyte/macrophage infiltration together with an increased interstitial collagen from 2.7+/-0.3 to 11.7+/-1.3%, increased passive diastolic stiffness (UNX 21.1+/-0.5, DOCA-salt 30.1+/-1.3*), prolongation of the action potential duration at 20 and 90% of repolarisation (APD20-UNX 6.8+/-1.1, DOCA-salt 10.1+/-1.5* ms; APD90-UNX 34.4+/-3.5 ms, DOCA-salt 64.3+/-10.4* ms) and vascular dysfunctions (2.6-fold decrease in maximal contractile response to noradrenaline, 3.5-fold decrease in maximal relaxation response to acetylcholine). Administration of A-127722 for 14 days starting 14 days after surgery attenuated the increases in systolic BP (150+/-6** mmHg, **P<0.05 vs DOCA-salt), left ventricular wet weight (2.65+/-0.06** mg kg(-1) body wt) and internal diameter (6.39+/-0.31** mm), prevented left ventricular monocyte/macrophage accumulation, attenuated the increased left ventricular interstitial collagen (7.6+/-1.3%**), reversed the increased passive diastolic stiffness (22.1+/-1.2**), attenuated the action potential duration prolongation (APD20 - 7.6+/-1.4**, APD90 - 41.5+/-6.9** ms) and normalised changes in vascular function. ET-A receptor antagonism both reverses and prevents the cardiac and vascular remodelling in DOCA-salt hypertension and improves cardiovascular function.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Daily water intake measurements for UNX (n=21), UNX+A-127722 (n=16), DOCA-salt (n=36) and DOCA-salt+A-127722 (n=20) treated rats; *P<0.05 vs UNX rats.
Figure 2
Figure 2
Daily body weight measurements for UNX (n=21), UNX+A-127722 (n=16), DOCA-salt (n=36) and DOCA-salt+A-127722 (n=20) treated rats; *P<0.05 vs UNX rats.
Figure 3
Figure 3
Daily A-127722 dose for UNX+A-127722 (n=16) and DOCA-salt+A-127722 (n=20).
Figure 4
Figure 4
Immunohistochemical analysis of ED1 cells in left ventricular interstitium; *P<0.05 vs UNX rats; **P<0.05 vs DOCA-salt rats.
Figure 5
Figure 5
Representative action potentials (a) and action potential durations (b) at 20, 50 and 90% repolarisation in isolated papillary muscles from UNX (n=8), UNX+A-127722 (n=6), DOCA-salt (n=6 at 2 weeks, n=8 at 4 weeks) and DOCA-salt+A-127722 (n=8) treated rats; *P<0.05 vs UNX rats, **P<0.05 vs DOCA-salt rats (4 weeks), #P<0.05 vs DOCA-salt rats (2 weeks).
Figure 6
Figure 6
Cumulative concentration–response curves for (a) noradrenaline, (b) acetylcholine and (c) sodium nitroprusside in thoracic aortic rings from UNX (n=12), UNX+A-127722 (n=7), DOCA-salt (n=7 at 2 weeks, n=12 at 4 weeks) and DOCA-salt+A-127722 (n=8) treated rats; maximal contractile response to noradrenaline from UNX (9.9±1.9 mN), UNX+A-127722 (9.4±1.3 mN), DOCA-salt 2 weeks (8.9±1.3 mN), DOCA-salt 4 weeks (4.7±0.5*# mN) and DOCA-salt+A-127722 (8.8±1.6** mN); maximal contractile response to potassium chloride (100 mM) from UNX (13.9±4.2 mN), UNX+A-127722 (15.5±1.6 mN), DOCA-salt 2 weeks (10.5±3.8 mN), DOCA-salt 4 weeks (5.4±0.6* mN) and DOCA-salt+A-127722 (10.1±1.8** mN); maximal relaxant response to acetylcholine from UNX (5.2±1.9 mN), UNX+A-127722 (5.4±0.2 mN), DOCA-salt 2 weeks (2.9±0.8* mN), DOCA-salt 4 weeks (1.8±0.4* mN) and DOCA-salt+A-127722 (3.9±0.9** mN); maximal relaxant response to sodium nitroprusside from UNX (8.3±1.9 mN), UNX+A-127722 (9.1±1.5 mN), DOCA-salt 2 weeks (9.2±2.7 mN), DOCA-salt 4 weeks (6.1±1.8 mN) and DOCA-salt+A-127722 (9.9±2.3 mN); *P<0.05 vs UNX rats; **P<0.05 vs DOCA-salt rats, #P<0.05 vs DOCA-salt rats (2 weeks).

References

    1. AMMARGUELLAT F., LAROUCHE I., SCHIFFRIN E.L. Myocardial fibrosis in DOCA-salt hypertensive rats. Effects of endothelin ETA receptor antagonism. Circulation. 2001;103:319–324. - PubMed
    1. AMMARGUELLAT F.Z., GANNON P.O., AMIRI F., SCHIFFRIN E.L. Fibrosis, matrix metalloproteinases, and inflammation in the heart of DOCA-salt hypertensive rats: role of ETA receptors. Hypertension. 2002;39:679–684. - PubMed
    1. BALTOGIANNIS G.G., TSALIKAKIS D.G., MITSI A.C., HATZISTERGOS K.E., ELAIOPOULOS D., FOTIADIS D.I., KYRIAKIDES Z.S., KOLETTIS T.M. Endothelin receptor-A blockade decreases ventricular arrhythmias after myocardial infarction in rats. Cardiovasc. Res. 2005;67:647–654. - PubMed
    1. BESWICK R.A., ZHANG H., MARABLE D., CATRAVAS J.D., HILL W.D., WEBB R.C. Long-term antioxidant administration attenuates mineralocorticoid hypertension and renal inflammatory response. Hypertension. 2001;37:781–786. - PubMed
    1. BROWN L., CRAGOE E.J., JR, ABEL K.C., MANLEY S.W., BOURKE J.R. Amiloride analogues induce responses in isolated rat cardiovascular tissues by inhibition of Na+/Ca2+ exchange. Naunyn-Schmiedeberg's Arch. Pharmacol. 1991;344:220–224. - PubMed

Publication types

MeSH terms